Phase 1 Study of URC102 in Healthy Subjects

Phase 1CompletedNCT01953497

JW Pharmaceutical81 enrolled

Overview

To assess the safety, tolerability, PK and PD of URC102 in healthy subjects. To evaluate the food effect on PK.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Healthy

Interventions

URC102DRUG

PlaceboDRUG

Eligibility

Sex: MALEMin age: 20 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy male volunteers Exclusion Criteria: * Received other investigational drug within 12 weeks prior to the first dose of study drug

Locations (1)

Seoul National University Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

Number of participants with AE

Time frame: 1 week

Secondary Outcomes

Plasma URC102 concentration

Time frame: 1 week

Blood uric acid

Time frame: 1 week

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.